Effects of Long-acting Injectable 3-Monthly Paliperidone Palmitate on the Clinical and Social Performance of Patients with Schizophrenia
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objective: To investigate the effects of long-acting injectable 3-monthly paliperidone palmitate on the clinical and social functioning of patients with schizophrenia. Methods: This study enrolled patients with schizophrenia receiving long-acting injectable 1-monthly paliperidone palmitate for at least 4 months and who subsequently received 3-monthly paliperidone palmitate. Accordingly, 418 patients were followed up for 24 weeks. Their clinical symptoms and social functioning were measured using the Clinical Global Impression-Severity of Illness and Personal and Social Performance scales. Results: The Personal and Social Performance total score was significantly higher after 3-monthly paliperidone palmitate treatment than at baseline (baseline vs. week 24: 54.3 ± 18.0 vs. 61.0 ± 14.5 [mean ± standard deviation]; p ＜ 0.001; Wilcoxon signed-rank test); the proportion of patients in the mildly ill group (scores 71−100) also increased significantly (baseline vs. week 24: 16.5% vs. 20.6%; p ＜ 0.001; McNemar-Bowker test). The mean Clinical Global Impression-Severity of Illness score decreased significantly (baseline vs. week 24: 3.7 ± 1.0 vs. 3.4 ± 0.9; p ＜ 0.001; Wilcoxon signed-rank test), as did the proportion of patients in the severely ill group (baseline vs. week 24: 4.1% vs. 2.1%; p ＜ 0.001; McNemar-Bowker test). Conclusion: Continuous 3-monthly paliperidone palmitate treatment significantly enhances the personal and social performance of patients with schizophrenia and reduces the proportion of those with severe illness. These findings suggest that long-acting injectable antipsychotic administration at intervals longer than 1 month might improve the social functioning of and promote return to activities of daily living in patients with schizophrenia.
Abstract
Objective: To investigate the effects of long-acting injectable 3-monthly paliperidone palmitate on the clinical and social functioning of patients with schizophrenia. Methods: This study enrolled patients with schizophrenia receiving long-acting injectable 1-monthly paliperidone palmitate for at least 4 months and who subsequently received 3-monthly paliperidone palmitate. Accordingly, 418 patients were followed up for 24 weeks. Their clinical symptoms and social functioning were measured using the Clinical Global Impression-Severity of Illness and Personal and Social Performance scales. Results: The Personal and Social Performance total score was significantly higher after 3-monthly paliperidone palmitate treatment than at baseline (baseline vs. week 24: 54.3 ± 18.0 vs. 61.0 ± 14.5 [mean ± standard deviation]; p ＜ 0.001; Wilcoxon signed-rank test); the proportion of patients in the mildly ill group (scores 71−100) also increased significantly (baseline vs. week 24: 16.5% vs. 20.6%; p ＜ 0.001; McNemar-Bowker test). The mean Clinical Global Impression-Severity of Illness score decreased significantly (baseline vs. week 24: 3.7 ± 1.0 vs. 3.4 ± 0.9; p ＜ 0.001; Wilcoxon signed-rank test), as did the proportion of patients in the severely ill group (baseline vs. week 24: 4.1% vs. 2.1%; p ＜ 0.001; McNemar-Bowker test). Conclusion: Continuous 3-monthly paliperidone palmitate treatment significantly enhances the personal and social performance of patients with schizophrenia and reduces the proportion of those with severe illness. These findings suggest that long-acting injectable antipsychotic administration at intervals longer than 1 month might improve the social functioning of and promote return to activities of daily living in patients with schizophrenia.
참고문헌 (26)
- McCutcheon RA, "Schizophrenia-an overview", JAMA Psychiatry, 77, pp.201~210 (2020)
- Hui CLM, "A systematic review of clinical guidelines on choice, dose, and duration of antipsychotics treatment in first-and multi-episode schizophrenia", Int Rev Psychiatry, 31, pp.441~459 (2019)
- Johnstone EC, "Mechanism of the antipsychotic effect in the treatment of acute schizophrenia", Lancet, 1, pp.848~851 (1978)
- Novick D, "Real-world effectiveness of antipsychotics for the treatment of negative symptoms in patients with schizophrenia with predominantly negative symptoms", Pharmacopsychiatry, 50, pp.56~63 (2017)
- Robinson DG, "Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder", Schizophr Res, 57, pp.209~219 (2002)
- Hirsch L, "Second-generation antipsychotics and metabolic side effects : a systematic review of population-based studies", Drug Saf, 40, pp.771~781 (2017)
- MacKenzie NE, "Antipsychotics, metabolic adverse effects, and cognitive function in schizophrenia", Front Psychiatry, 9, pp.622~ (2018)
- Taipale H, "20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62, 250 patients with schizophrenia(FIN20)", World Psychiatry, 19, pp.61~68 (2020)
- Oh J, "Decreased cardiovascular death in schizophrenia patients treated with antipsychotics : a Korean national cohort study", Schizophr Res, 228, pp.417~424 (2021)
- Correll CU, "Using long-acting injectable antipsychotics to enhance the potential for recovery in schizophrenia", J Clin Psychiatry, 81 (2020)
- Miyamoto S, "The use of long-acting injectable antipsychotics in schizophrenia", Curr Treat Options Psychiatry, 4, pp.117~126 (2017)
- Kaplan G, "Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia", Patient Prefer Adherence, 7, pp.1171~1180 (2013)
- Kane JM, "Effect of long-acting injectable antipsychotics vs usual care on time to first hospitalization in early-phase schizophrenia : a randomized clinical trial", JAMA Psychiatry, 77, pp.1217~1224 (2020)
- Kim S, "Effects of long-acting injectable paliperidone palmitate on clinical and functional outcomes in patients with schizophrenia based on illness duration", J Clin Psychiatry, 82, pp.20~ (2021)
- Citrome L, "Long-acting injectable antipsychotics : what, when, and how", CNS Spectr, 26, pp.118~129 (2021)
- Nasrallah HA, "The case for long-acting antipsychotic agents in the post-CATIE era", Acta Psychiatr Scand, 115, pp.260~267 (2007)
- Barnes TR, "Screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics : a quality improvement programme", Acta Psychiatr Scand, 118, pp.26~33 (2008)
- Busner J, "The clinical global impressions scale:applying a research tool in clinical practice", Psychiatry(Edgmont), 4, pp.28~37 (2007)
- Brissos S, "Is personal and social functioning associated with subjective quality of life in schizophrenia patients living in the community?", Eur Arch Psychiatry Clin Neurosci, 261, pp.509~517 (2011)
- Viala A, "Treatment adherence with early prescription of long-acting injectable antipsychotics in recent-onset schizophrenia", Schizophr Res Treatment, 2012, pp.368687~ (2012)
- Berwaerts J, "Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia : a randomized clinical trial", JAMA Psychiatry, 72, pp.830~839 (2015)
- Nasrallah H, "Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia", Psychiatry Res, 161, pp.213~224 (2008)
- Goldman LS, "Medical illness in patients with schizophrenia", J Clin Psychiatry, 60(Suppl 21), pp.10~15 (1999)
- Lambert TJ, "Medical comorbidity in schizophrenia", Med J Aust, 178(S9), pp.S67~S70 (2003)
- Dixon L, "The association of medical comorbidity in schizophrenia with poor physical and mental health", J Nerv Ment Dis, 187, pp.496~502 (1999)
- Jelastopulu E, "Correlation between the Personal and Social Performance scale(PSP)and the Positive and Negative Syndrome Scale(PANSS)in a Greek sample of patients with schizophrenia", BMC Psychiatry, 14, pp.197~ (2014)